Oral cladribine reshapes CSF immune cell composition in relapsing multiple sclerosis
Cladribine therapy changes immune cells in fluid from the brain in a small MS study
This single-site phase IV clinical trial used single-cell sequencing on CSF and blood from 13 individuals with relapsing MS before and after…
Cladribine therapy reshapes immune cells in the brain's fluid by reducing harmful memory B cells while boosting protective Treg cells in mul…
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184). Seri…
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…